Nacolomab

Nacolomab is a monoclonal antibody for the treatment of cancer. This drug was developed by Neoprobe Corporation.

History

Nacolomab was originally developed by Neoprobe Corporation, a biopharmaceutical company specializing in the development of oncology and cardiovascular surgical and diagnostic products. The drug is a monoclonal antibody, a type of protein made in the laboratory that can bind to substances in the body, including cancer cells.

Mechanism of Action

As a monoclonal antibody, Nacolomab works by targeting and binding to specific cells or proteins, which stimulates the body's immune system to attack those cells. This is a common mechanism of action for many cancer treatments, as it allows for targeted therapy that can minimize damage to healthy cells.

Clinical Trials

Nacolomab has undergone various clinical trials to assess its safety and efficacy in treating cancer. These trials are crucial steps in the drug development process, as they provide the data necessary for regulatory approval.

Side Effects

Like all drugs, Nacolomab can cause side effects. The nature and severity of these side effects can vary widely and are often dependent on the dosage and duration of treatment.

See Also

• Monoclonal antibodies
• Cancer treatment
• Clinical trials
• Neoprobe Corporation

Nacolomab Resources
Latest articles Most recent articles Ongoing trials	Wikipedia